Page 138 - Read Online

SVR; [11,26] many metabolic processes may be involved, Surg Res 2005;128:147-56.
related to the reduction in the oestrogen serum 2. Shimizu I, Kohno N, Tamaki K, Shono M, Huang HW, He JH,
Yao DF. Female hepatology: favorable role of estrogen in chronic
[27]
concentration after menopause, although it has liver disease with hepatitis B virus infection. World J Gastroenterol
been not separately considered in our study; many 2007;13:4295-305.
data from literature suggested as the reproductive 3. Ismail N, Fish GE, Smith MB. Laboratory evaluation of a fully
automated chemiluminescence immunoassay for rapid detection of
state may be an important factor in predicting the HBsAg, antibodies to HBsAg, and antibodies to hepatitis C virus. J
[26]
response to antiviral therapy. These observations Clin Microbiol 2004;42:610-7.
suggest as women in reproductive age with CHC 4. Jonas G, Pelzer C, Beckert C, Hausmann M, Kapprell HP.
Performance characteristics of the ARCHITECT anti-HCV assay. J
should be treated even if liver disease is moderate, Clin Virol Off Publ Pan Am Soc Clin Virol 2005;34:97-103.
being this condition linked to oestrogens exposure. [28] 5. Krajden M, Ziermann R, Khan A, Mak A, Leung K, Hendricks D,
et al. Qualitative detection of hepatitis C virus RNA: comparison
Results obtained from our comparison between of analytical sensitivity, clinical performance, and workflow of
the Cobas Amplicor HCV test version 2.0 and the HCV RNA
younger and elder women and younger and elder transcription-mediated amplification qualitative assay. J Clin
men showed in the group of women a meaningful Microbiol 2002;40:2903-7.
worsening in > 50 year-old patients compared 6. Pittaluga F, Allice T, Abate ML, Ciancio A, Cerutti F, Varetto S,
Colucci G, Smedile A, Ghisetti V. Clinical evaluation of the COBAS
to younger ones whilst this difference was not so Ampliprep/COBAS TaqMan for HCV RNA quantitation in comparison
significant in the group of men although there was with the branched-DNA assay. J Med Virol 2008;80:254-60.
a worse response after 50 years. This suggested the 7. Elbeik T, Surtihadi J, Destree M, Gorlin J, Holodniy M, Jortani
lost of the advantage in female gender after 50 years SA, Kuramoto K, Ng V, Valdes R Jr, Valsamakis A, Terrault NA.
Multicenter evaluation of the performance characteristics of the
without having a worsening in both genders with age. bayer VERSANT HCV RNA 3.0 assay (bDNA). J Clin Microbiol
2004;42:563-9.
In summary, even if affected by limitations related 8. Sizmann D, Boeck C, Boelter J, Fischer D, Miethke M, Nicolaus
S, Zadak M, Babiel R. Fully automated quantification of hepatitis C
to retrospective and in subgroups analysis, the virus (HCV) RNA in human plasma and human serum by the COBAS
outcomes we obtained reveal not meaningful AmpliPrep/COBAS TaqMan system. J Clin Virol 2007;38:326-33.
differences between men and women when the 9. Nolte FS, Green AM, Fiebelkorn KR, Caliendo AM, Sturchio
C, Grunwald A, Healy M. Clinical evaluation of two methods for
whole sample is examined without stratification by genotyping hepatitis C virus based on analysis of the 5’ noncoding
age whilst an influence of gender on the response region. J Clin Microbiol 2003;41:1558-64.
to the treatment is identified when patients were 10. Armstrong MJ, Corbett C, Hodson J, Marwah N, Parker R, Houlihan
divided in two groups younger or elder than 50 DD, Rowe IA, Hazlehurst JM, Brown R, Hübscher SG, Mutimer D.
Operator training requirements and diagnostic accuracy of Fibroscan
years. Despite the grade of influence of gender on in routine clinical practice. Postgrad Med J 2013; 89:685-92.
standard treatment is still debated, we noticed as 11. Codes L, Asselah T, Cazals-Hatem D, Tubach F, Vidaud D, Paraná R,
the female gender may be considered a positive Bedossa P, Valla D, Marcellin P. Liver fibrosis in women with chronic
hepatitis C: evidence for the negative role of the menopause and
predictor of response to therapy, taking into account steatosis and the potential benefit of hormone replacement therapy.
its strong interaction with age and inserting in a Gut 2007;56:390-5.
broader context made of several modifiable and 12. Fierbinţeanu-Braticevici C, Mohora M, Tribus L, Petrişor A, Creţoiu
SM, Creţoiu D, Usvat R, Ioniţă L. Hepatocyte steatosis in patients
non-modifiable predictive factors related to the infected with genotype 1 hepatitis C virus. Romanian J Morphol
host and virus. Considering both high efficacy and Embryol 2010;51:235-42.
costs of new antiviral drugs therapy protocols, the 13. Villa E, Karampatou A, Cammà C, Di Leo A, Luongo M, Ferrari A,
Petta S, Losi L, Taliani G, Trande P, Lei B, Graziosi A, Bernabucci V,
evidence of a gender- and age- different response to Critelli R, Pazienza P, Rendina M, Antonelli A, Francavilla A. Early
the standard treatment may play a role in changing menopause is associated with lack of response to antiviral therapy in
women with chronic hepatitis C. Gastroenterology 2011;140:818-29.
epidemiologic characteristics of eligible patients and 14. Rigamonti C, Andorno S, Maduli E, Capelli F, Boldorini R, Sartori
asks the question if certain groups of patients should M. Gender and liver fibrosis in chronichepatitis: the role of iron
be primarily treated. status. Aliment Pharmacol Ther 2005;21:1445-51.
15. Lao XQ, Thompson A, McHutchison JG, McCarthy JJ. Sex and age
Financial support and sponsorship differences in lipid response to chronic infection with the hepatitis C
virus in the United States National Health and Nutrition Examination
Nil. Surveys. J Viral Hepat 2011;18:571-9.
16. Bakr I, Rekacewicz C, El Hosseiny M, Ismail S, El Daly M, El-
Conflicts of interest Kafrawy S, Esmat G, Hamid MA, Mohamed MK, Fontanet A.
There are no conflicts of interest. Higher clearance of hepatitis C virus infection in females compared
with males. Gut 2006;55:1183-7.
17. Aziz H, Gil ML, Waheed Y, Adeeb U, Raza A, Bilal I, Athar MA.
REFERENCES Evaluation of prognostic factors for Peg Interferon alfa-2b plus
ribavirin treatment on HCV infected patients in Pakistan. Infect
1. Yokoyama Y, Nimura Y, Nagino M, Bland KI, Chaudry IH. Current Genet Evol 2011;11:640-5.
understanding of gender dimorphism in hepatic pathophysiology. J 18. Idrees M, Riazuddin S. A study of best positive predictors for

Hepatoma Research | Volume 2 | May 6, 2016 129